D.E. Shaw & Co
STSA

D.E. Shaw & Co’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

D.E. Shaw & Co’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,232
Closed -$52K – 5827
2021
Q3 		$52K Sell
11,232
-3,396
-23% -$18K ﹤0.01% 4819
2021
Q2 		$103K Buy
+14,628
New +$78.9K ﹤0.01% 4549

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co's STSA Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2021, closing a stake of 11,232 shares — an estimated $52K sold.

D.E. Shaw & Co first reported a position in STSA in Q2 2021 and held it in 2 quarters. The position peaked at $103K in Q2 2021. 35 funds tracked by Wall St. Rank hold STSA as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 11,232 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $52K.
  • D.E. Shaw & Co first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $103K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.